2000
Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness M, Kenney J, Reiss M, Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Research 2000, 60: 5354-8. PMID: 11034070.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusPosttransplant lymphoproliferative disorderLymphoproliferative disordersBcl-2 antisenseLymphoproliferative diseaseImmunodeficient miceEpstein-Barr virus-associated lymphoproliferative diseaseBcl-2EBV-positive lymphoproliferative diseaseSequence-dependent antitumor effectsMajority of EBVAntisense oligodeoxynucleotide therapyEBV-positive malignanciesB-cell lymphoproliferationBcl-2 antisense therapyInhibition of proliferationLymphoblastoid B cellsTreatment strategiesChemoprotective effectsAntitumor effectsVitro treatmentB cellsChimeric modelDecreased expressionRational targetAntisense to the Epstein‐Barr virus (EBV)‐encoded latent membrane protein 1 (LMP‐1) sensitizes EBV‐immortalized B cells to transforming growth factor‐beta and chemotherapeutic agents
Kenney J, Guinness M, Reiss M, Lacy J. Antisense to the Epstein‐Barr virus (EBV)‐encoded latent membrane protein 1 (LMP‐1) sensitizes EBV‐immortalized B cells to transforming growth factor‐beta and chemotherapeutic agents. International Journal Of Cancer 2000, 91: 89-98. PMID: 11149426, DOI: 10.1002/1097-0215(20010101)91:1<89::aid-ijc1015>3.0.co;2-u.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicApoptosisB-LymphocytesCell DivisionCell Line, TransformedCell SeparationCyclin D2CyclinsDexamethasoneDNA, AntisenseDown-RegulationEtoposideFlow CytometryHumansImmunoblottingLymphomaMyeloid Cell Leukemia Sequence 1 ProteinNeoplasm ProteinsProto-Oncogene Proteins c-bcl-2Transforming Growth Factor betaTumor Cells, CulturedVincristineViral Matrix ProteinsConceptsLatent membrane protein 1Epstein-Barr virusLymphoblastoid cell linesLMP-1B cellsMembrane protein 1Antisense oligodeoxynucleotidesEBV-positive lymphoproliferative disordersChemotherapeutic agentsEBV-positive lymphoblastoid cell linesEBV-positive cell linesProtein 1Human B cell growthAntisense treatmentApoptotic effectsRational therapeutic targetShort-term treatmentLMP-1 expressionRational therapeutic strategiesB cell growthCell linesLMP-1 proteinTumor necrosis factor receptor familyInhibition of proliferationLymphoproliferative disorders
1996
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Of Clinical Oncology 1996, 14: 1943-9. PMID: 8656264, DOI: 10.1200/jco.1996.14.6.1943.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusMTX withdrawalLymphoproliferative disordersComplete remissionPolymerase chain reactionRheumatic diseasesPartial responseAbsence of EBVNegative Epstein-Barr virusEBV RNA transcriptsSpontaneous complete remissionLow-grade lymphomaCNS involvementExtranodal diseaseImmunosuppressive therapyMethotrexate therapyMTX therapyInitial managementAggressive lymphomaClinicopathologic featuresHodgkin's diseasePathologic findingsRheumatoid arthritisSitu hybridization studiesSpontaneous regression